Celgene seeks dismissal of amended US antitrust claims over Thalomid, Revlimid
MLex Summary: Celgene and Bristol-Myers Squibb, along with Teva Pharmaceuticals and other drug manufacturers asked a New Jersey federal judge to dismiss with prejudice amended antitrust claims brought by plaintiffs alleging...To view the full article, register now.
Already a subscriber? Click here to view full article